Advancing Diagnostic Solutions for Myeloid Malignancies

• Direct contact technical support
• Find products for your research

Invivoscribe is dedicated to advancing diagnostic solutions for the characterization and treatment of myeloid malignancies. These malignancies include both chronic conditions like myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML), and acute stages such as acute myeloid leukemia (AML).

Download Invivoscribe’s
Hematological Testing Menu

Comprehensive Solutions for AML & Related Neoplasms

Acute myeloid leukemia (AML) and related neoplasms are aggressive disorders characterized by the rapid proliferation of abnormal myeloid cells. Early and accurate diagnosis is crucial for improving patient outcomes. Our diagnostic products and services are designed to help physicians make more informed treatment decisions through precise, reliable testing.

FLT3 Testing for Personalized Treatment Plans

Mutations in the FLT3 gene are commonly found in AML patients and are associated with a higher risk of relapse and poor prognosis. Invivoscribe offers a range of globally standardized FLT3 testing solutions that provide essential data, enabling clinicians to tailor treatment plans and monitor therapy response effectively.

IVDR Approved LeukoStrat® CDx FLT3 Mutation Assay

Now available in regions where CE 2797 IVD approved products are sold. The LeukoStrat® CDx FLT3 Mutation Assay is a globally standardized, PCR-based in vitro diagnostic test used to detect FLT3 mutations in AML patients. This test plays a critical role in making treatment decisions by identifying prognostic mutations that are also clinically actionable.

Download flyer

Advanced Monitoring with FLT3 ITD MRD Assay & NPM1 MRD Assay

We are also excited to offer the FLT3 ITD MRD Assay & Software and the NPM1 MRD Assay & Software, providing clinicians with the tools needed for enhanced disease monitoring:

• No baseline sample required
• FLT3 ITD MRD Assay detects and reports insertions ranging from 9 to 252 base pairs
• NPM1 MRD Assay detects and report mutations A, B, D, or ‘Other’
• Dockerized software is portable, automatable, and easily integrated into downstream reporting systems and/or LIMS
• High sensitivity with detection at 5 x 10⁻⁵

Learn more about the FLT3 ITD MRD Assay

Level Up your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

Watch webinar

Discover the latest key opinion leader publications

Featuring innovative approaches for measurable residual disease (MRD) detection using next-generation sequencing (NGS)

• Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia | Dillon et al. JAMA Oncol. 2024.
• Gilteritinib as Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3 | Levis et al. J Clin Oncol. 2024.
• Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated | Levis et al. Blood. 2023.

A Comprehensive Solution for AML Precision Diagnostics

To learn more about our AML solutions and their clinical applications, watch the following video:

Watch webinar